靶向CSPG4从体液中分离黑色素瘤细胞衍生的外泌体。
Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids.
作者信息
Ferrone S, Whiteside T L
机构信息
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, 02114, Boston, MA, USA.
Departments of Pathology, Immunology and Otolaryngology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, 15213, Pittsburgh, PA, USA.
出版信息
HNO. 2020 Feb;68(2):100-105. doi: 10.1007/s00106-019-00811-1.
Abstract
This manuscript describes the functional properties of the exosomes released from melanoma cells. It details the characteristics of the tumor antigen chondroitin sulfate proteoglycan 4 (CSPG4), which is used as a marker to separate exosomes released by melanoma cells from exosomes released by nonmalignant cells. The results are discussed in view of the potential role of melanoma cell-derived exosomes in the escape of malignant cells from the host's immune system.
摘要
本手稿描述了黑色素瘤细胞释放的外泌体的功能特性。它详细介绍了肿瘤抗原硫酸软骨素蛋白聚糖4（CSPG4）的特征，该抗原被用作将黑色素瘤细胞释放的外泌体与非恶性细胞释放的外泌体分离的标志物。鉴于黑色素瘤细胞衍生的外泌体在恶性细胞逃避宿主免疫系统中的潜在作用，对结果进行了讨论。
相似文献
1
Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids.靶向CSPG4从体液中分离黑色素瘤细胞衍生的外泌体。
HNO. 2020 Feb;68(2):100-105. doi: 10.1007/s00106-019-00811-1.
2
Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.硫酸软骨素蛋白聚糖 4 通过核心蛋白跨膜结构域中的半胱氨酸增强黑色素瘤的迁移和生长。
Melanoma Res. 2019 Aug;29(4):365-375. doi: 10.1097/CMR.0000000000000574.
3
Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.抗原模拟作为一种在患有口腔黑色素瘤的犬中诱导 CSPG4 靶向免疫的有效策略：一项兽医试验。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2021-004007.
4
Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity.在无自身免疫的情况下，黑色素瘤患者和健康个体中针对黑色素瘤相关硫酸软骨素蛋白聚糖的肿瘤反应性CD4 + T细胞应答。
J Immunol. 2007 Jun 15;178(12):7703-9. doi: 10.4049/jimmunol.178.12.7703.
5
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.抗硫酸软骨素蛋白聚糖4特异性抗体在常氧和缺氧条件下对维莫非尼对黑色素瘤细胞的作用有不同的影响。
Int J Oncol. 2015 Jul;47(1):81-90. doi: 10.3892/ijo.2015.3010. Epub 2015 May 18.
6
Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.靶向黑素瘤相关抗原 CSPG4 的 HLA-C*07:01 限制性 T 细胞受体。
Front Immunol. 2023 Oct 2;14:1245559. doi: 10.3389/fimmu.2023.1245559. eCollection 2023.
7
Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.硫酸软骨素蛋白聚糖-4：犬恶性黑色素瘤的生物标志物和潜在免疫治疗靶点。
Vet J. 2011 Nov;190(2):e26-e30. doi: 10.1016/j.tvjl.2011.02.020. Epub 2011 Apr 8.
8
Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.通过靶向 CSPG4 的免疫毒素的光化学内吞作用增强三阴性乳腺癌和恶性黑色素瘤的靶向性。
Photochem Photobiol Sci. 2018 May 16;17(5):539-551. doi: 10.1039/C7PP00358G.
9
Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma.黑色素瘤中硫酸软骨素蛋白聚糖4（CSPG4）的检测
Methods Mol Biol. 2014;1102:523-35. doi: 10.1007/978-1-62703-727-3_28.
10
Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.软骨素硫酸盐蛋白聚糖 4（CSPG4）在黑色素瘤细胞中的表达在 BRAF 抑制时下调。
Oncol Rep. 2021 Apr;45(4). doi: 10.3892/or.2021.7965. Epub 2021 Mar 2.
引用本文的文献
1
Scaffold-Free Functional Deconvolution Identifies Clinically Relevant Metastatic Melanoma EV Biomarkers.无支架功能反卷积鉴定出临床相关的转移性黑色素瘤细胞外囊泡生物标志物。
Cancers (Basel). 2025 Jul 30;17(15):2509. doi: 10.3390/cancers17152509.
2
MCSP metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization.MCSP转移起始细胞在人类黑色素瘤转移定植早期激活免疫抑制。
Nat Cancer. 2025 May 16. doi: 10.1038/s43018-025-00963-w.
3
Tumor-derived Exosomes and Antitumor Immunity.肿瘤来源的外泌体与抗肿瘤免疫。
J Immunol. 2024 Oct 1;213(7):923-931. doi: 10.4049/jimmunol.2400335.
4
Enrichment, Characterization, and Proteomic Profiling of Small Extracellular Vesicles Derived from Human Limbal Mesenchymal Stromal Cells and Melanocytes.人角膜缘间充质基质细胞和黑色素细胞来源的小细胞外囊泡的富集、鉴定和蛋白质组学分析。
Cells. 2024 Apr 4;13(7):623. doi: 10.3390/cells13070623.
5
Diagnostic potential of exosomal extracellular vesicles in oncology.外泌体细胞外囊泡在肿瘤学中的诊断潜力。
BMC Cancer. 2024 Mar 8;24(1):322. doi: 10.1186/s12885-024-11819-4.
6
Size-exclusion chromatography combined with DIA-MS enables deep proteome profiling of extracellular vesicles from melanoma plasma and serum.尺寸排阻色谱法结合 DIA-MS 能够对黑色素瘤血浆和血清中的细胞外囊泡进行深度蛋白质组分析。
Cell Mol Life Sci. 2024 Feb 14;81(1):90. doi: 10.1007/s00018-024-05137-y.
7
Tumour-derived extracellular vesicle based vaccines for melanoma treatment.基于肿瘤细胞外囊泡的疫苗治疗黑色素瘤。
Drug Deliv Transl Res. 2023 May;13(5):1520-1542. doi: 10.1007/s13346-023-01328-5. Epub 2023 Apr 6.
8
Evaluating tumor cell- and T cell-derived extracellular vesicles as potential biomarkers of cancer and immune cell competence.评估肿瘤细胞和 T 细胞衍生的细胞外囊泡作为癌症和免疫细胞功能的潜在生物标志物。
Expert Rev Mol Diagn. 2023 Feb;23(2):109-122. doi: 10.1080/14737159.2023.2178902. Epub 2023 Feb 18.
9
Proteomic and Metabolomic Profiles of T Cell-Derived Exosomes Isolated from Human Plasma.从人血浆中分离的 T 细胞来源外泌体的蛋白质组学和代谢组学特征。
Cells. 2022 Jun 18;11(12):1965. doi: 10.3390/cells11121965.
10
Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.犬黑色素瘤免疫学与免疫疗法：转化研究的相关性
Front Vet Sci. 2022 Feb 11;9:803093. doi: 10.3389/fvets.2022.803093. eCollection 2022.
本文引用的文献
1
Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells.黑色素瘤患者血浆中的黑色素瘤细胞衍生的外泌体抑制免疫效应细胞的功能。
Sci Rep. 2020 Jan 9;10(1):92. doi: 10.1038/s41598-019-56542-4.
2
Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.接受伊匹单抗联合抗 PD-1 治疗的黑色素瘤患者的特定部位反应模式、假性进展和获得性耐药。
Cancer. 2020 Jan 1;126(1):86-97. doi: 10.1002/cncr.32522. Epub 2019 Oct 4.
3
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.PD-L1 分布与癌症免疫治疗的前景——阻断、敲低或抑制。
Front Immunol. 2019 Aug 27;10:2022. doi: 10.3389/fimmu.2019.02022. eCollection 2019.
4
Immunotherapy of Melanoma: Facts and Hopes.黑色素瘤的免疫治疗：现状与展望。
Clin Cancer Res. 2019 Sep 1;25(17):5191-5201. doi: 10.1158/1078-0432.CCR-18-1550. Epub 2019 Mar 28.
5
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.外泌体 PD-L1 有助于免疫抑制，并与抗 PD-1 反应相关。
Nature. 2018 Aug;560(7718):382-386. doi: 10.1038/s41586-018-0392-8. Epub 2018 Aug 8.
6
The emerging roles of exosomes in the modulation of immune responses in cancer.外泌体在癌症中免疫应答调节中的新兴作用。
Genome Med. 2018 Mar 26;10(1):23. doi: 10.1186/s13073-018-0535-4.
7
Cancer immunotherapy using checkpoint blockade.使用免疫检查点阻断的癌症免疫疗法。
Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22.
8
Myeloid derived-suppressor cells: their role in cancer and obesity.髓系来源抑制细胞：它们在癌症和肥胖中的作用。
Curr Opin Immunol. 2018 Apr;51:68-75. doi: 10.1016/j.coi.2018.03.007. Epub 2018 Mar 13.
9
Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma.基于免疫亲和从黑色素瘤患者血浆中分离黑色素瘤细胞衍生的外泌体。
J Extracell Vesicles. 2018 Feb 15;7(1):1435138. doi: 10.1080/20013078.2018.1435138. eCollection 2018.
10
Defective HLA class I antigen processing machinery in cancer.肿瘤中 HLA I 类抗原加工机制缺陷。
Cancer Immunol Immunother. 2018 Jun;67(6):999-1009. doi: 10.1007/s00262-018-2131-2. Epub 2018 Feb 27.
Zotero 插件